The Global Throat Cancer Diagnostics Market is expected to grow with a CAGR of 7.4% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below.
Access Full Report at @ https://www.databridgemarketresearch.com/reports/global-throat-cancer-diagnostics-market
The global throat cancer diagnostics market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenarios.
The major players in the global throat cancer diagnostics market are introducing a strong range of products with various applications and adopting strategic initiatives such as announcements, achievements, and innovation in the market. This helped companies to maximize sales with an enhanced services portfolio.
For instance,
- In July 2022, FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announced the opening of two new "NURA" health screening centers focusing on cancer and lifestyle diseases screening in India. The new NURA centers will open in Gurugram on July 21 this year and in Mumbai in September of the same year. This has helped the company to get expanded globally
F. Hoffmann-La Roche Ltd is the market leader in the global throat cancer diagnostics market. The other players in this market are FUJIFILM Corporation, Thermo Fisher Scientific Inc., CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips N.V., Merck KGaA, BD, General Electric Company, Illumina, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Abbott, QIAGEN, Siemens Healthcare GmbH, Myriad Genetics Inc., Quest Diagnostics Incorporated, Hologic, FONAR Corp., Time Medical Holding., Medonica Co. LTD, SternMed GmbH., MinFound Medical Systems Co., Ltd, PlexBio. And Beijing O&D Biotech Co., Ltd. among others.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland, and was founded in 1896. The company focuses on finding new medicines and diagnostics techniques to help patients live longer and better lives. The company operates business segments such as pharmaceuticals and diagnostics, where diagnostics is the market-focused business segment. The company offer product categories such as pharma and diagnostics, where diagnostics is the market-focused product category.
The company has subsidiaries which are Roche Algeria SPA, Roche Diabetes Care Argentina S.A., Roche Diagnostics Australia Pty Limited, Roche Austria GmbH, and Roche Bangladesh Limited among others. The company has a presence in America, Europe, Africa, Asia, and Oceania.
For instance,
- In May 2020, F. Hoffmann-La Roche Ltd totally acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation
FUJIFILM Corporation
FUJIFILM Corporation is headquartered in Tokyo, Japan, and was founded in 2006. The company focuses on providing products and services in healthcare, materials, and imaging. The company operates business segments such as healthcare, materials, and imaging, where healthcare is the market-focused business segment. The company offers product categories such as consumer products, healthcare products, business products, and others, where healthcare products is the market-focused product category.
The company has subsidiaries which are Fujifilm Irvine Scientific, Inc. Perseus proteomics, Fujifilm Electronic materials, Fujifilm UK Limited, Black Photo Corporation, among others. The company has a presence in North America, Europe, the Middle East and Africa, Asia-Pacific, and South America.
For instance,
- In July 2022, FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announced the opening of two new "NURA" health screening centers focusing on cancer and lifestyle diseases screening in India. The new NURA centers opened in Gurugram on July 21, 2022, and in Mumbai in September of the same year. This helped the company to get expanded globally
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is headquartered in Massachusetts, U.S., and was founded in 1956. The company focuses on fulfilling customers' needs to make the world healthier, cleaner, and safer. The company operates business segments such as analytical instruments, specialty diagnostics, life sciences solutions, laboratory products, and biopharma services, where specialty diagnostics is the market-focused business segment. The company offers product categories such as life sciences, industrial & applied science, clinical & diagnostics, lab solutions, and digital solutions, where clinical & diagnostics is the market-focused product category.
The company has a presence in North America, Europe, and Asia-Pacific.
For instance,
- In October 2022, Thermo Fisher Scientific Inc. announced that it is going to expand its laboratory operations in Highland Heights, Kentucky, helping customers deliver life-changing medicines to patients. The current facility, which includes central lab and biomarker operations, provides biopharma customers with high-quality laboratory services to accelerate drug development. This has helped the company to expand its clinical diagnostics business across various regions of the world and helped to increase its global presence in the market.
